Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, December 20, 2014
 
Register | Sign in
Home Page > Application Notes
  Application Notes
Scientific News
New And Beneficial Function Of Endogenous Retroviruses In Immune Response Identified
ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Scientists Identify New and Beneficial Function of Endogenous Retroviruses
Researchers found that ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Cells Build 'Cupboards' To Store Metals
Lawrence Livermore researchers have discovered that cells of the alga Chlamydomonas Reinhardti build a “pantry” to store metal and maintain equilibrium.
Predicting Antibiotic Resistance
A common set of features appear to be responsible for the development of resistance to several types of antibiotics.
53 Approved Drugs that May Block Ebola Infection Identified
Compounds may keep virus from entering cells and could accelerate drug development.
Tailor-Made Cancer Treatments? New Cell Culture Technique Paves The Way
Technique grew cells from 73% of patients in the study, more than three times as effective as previous methods.
Non-Gluten Proteins as Targets of Immune Response to Wheat in Celiac Disease
The results were reported online in the Journal of Proteome Research.
New Research Unlocks a Mystery of Albinism
A team led by Brown University biologists has discovered the way in which a specific genetic mutation appears to lead to the lack of melanin production underlying a form of albinism.
Predicting Sepsis
Altered white-blood-cell motion in burn patients may warn of infection.
Study Finds Genetic Clue To Menopause-Like Condition In Young Women
NIH-funded research may also contribute to understanding normal menopause.
Scroll Up
Scroll Down

Efficient Delivery of Thermo Scientific Dharmacon SMARTpool siRNA Reagents in Difficult-to-Transfect Cell Lines Using Nucleofector® 96-well Shuttle® System
Bookmark and Share
Lonza


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza to Expand ADC Manufacturing Capacity
Capacity expansion is expected to be complete in the second quarter of 2014.
Thursday, January 10, 2013
Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.
Thursday, April 19, 2012
Lonza Appoints Richard Ridinger as New CEO
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.
Thursday, April 05, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.
Friday, May 18, 2007
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn